Cancer-specific mutations in PIK3CA are oncogenic in vivo - Wikidata - awgldk - TriplyDB

Cancer-specific mutations in PIK3CA are oncogenic in vivo

Cancer-specific mutations in PIK3CA are oncogenic in vivo

http://www.wikidata.org/entity/Q34335169

about

Gene expression profiling reveals new aspects of PIK3CA mutation in ERalpha-positive breast cancer: major implication of the Wnt signaling pathway Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy The PI3K pathway as drug target in human cancer Emerging common themes in regulation of PIKKs and PI3Ks Comprehensive genomic characterization defines human glioblastoma genes and core pathways Knockin of mutant PIK3CA activates multiple oncogenic pathways Targeting the mTOR signaling network for cancer therapy The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus Emerging molecular classifications and therapeutic implications for gastric cancer Use of the Chick Embryo Model in Uveal Melanoma PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma PI3K and AKT: Unfaithful Partners in Cancer The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond PI3K mutations in breast cancer: prognostic and therapeutic implications PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data Oncogenic mutations of PIK3CA in human cancers PI3K/PTEN signaling in angiogenesis and tumorigenesis The chick embryo as an expanding experimental model for cancer and cardiovascular research Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors Targeting the phosphoinositide 3-kinase pathway in cancer mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.Protooncogene TCL1b functions as an Akt kinase co-activator that exhibits oncogenic potency in vivo.Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Defining the blueprint of the cancer genome.Mutational profiling of kinases in human tumours of pancreatic origin identifies candidate cancer genes in ductal and ampulla of vater carcinomas.The PIK3CA gene as a mutated target for cancer therapy.Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS.ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors.Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic.The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

P2860

Q21135589-C706C60B-4CAC-46B3-81C2-886DC2917B4A Q24608709-BA97C48F-6DDD-48E9-9EAC-155D5F4ADB30 Q24628724-B02A5503-AAD6-409C-A654-3BFA56D0D6BD Q24632283-188EE47A-BAAB-4033-8AA4-C2AFA3E306B6 Q24647293-81DBDD03-3BC1-4A5A-A82B-970254C3E27E Q24656128-0F500D22-BD8E-4F4B-8244-1325ADCC5B60 Q24657412-B1A8EB02-27AA-42AE-9EDC-260045F3FCFB Q24658334-2904F6FF-3913-4AA3-95A2-7E4700FE89FD Q26740184-94804A47-9B75-4783-ADBE-18EFABE639AF Q26745525-F6492B28-F62D-4E95-AC76-47B7405A8FC8 Q26750391-82ABA735-072C-4F90-B587-2EAB5504DF4E Q26766293-34820106-8C8C-4CAF-8206-1C01110FB75E Q26781367-9A5FDCB6-EF79-4C63-B68B-77B6D035F0DF Q27649316-CE9975BF-5A7D-4F49-AFF2-C6BF3101AB12 Q27684091-8724146D-BA55-4513-BC30-01BCB2B68C1F Q28078957-7B4182B7-FDED-42A5-B21F-2AED85E53C2C Q28080730-88620E77-575E-4D12-BFEA-E1FB5936B322 Q28081992-69642A35-41D1-4F00-8242-7A363E16B63F Q28247338-7B11F0A7-0F1E-4A84-A9B4-95CB3330BFA8 Q28284802-DD34E588-4682-4293-96C7-A558B511DD78 Q28383083-E4F4850F-CA7F-4C93-AB87-C9B303F021BB Q28655771-5C406A6C-E6C1-48FE-A20E-7E2F2D02C2F7 Q28729079-A759DABA-048E-4DE7-AE1B-EEEF93CA085A Q29615809-7ABF3F59-9ECE-4A7C-96A8-B4470F5A469C Q30415483-70F7C982-EAEB-4E17-87B6-85123D1EE1F1 Q30492318-6106417B-4D02-4E6C-9405-5371C6650E89 Q30556645-73637DCE-EC2C-4D75-AC32-A377A5218CF6 Q33403197-6C4000DB-21E4-46F6-A1F6-96CEE1A5F64F Q33422258-A18AEF0F-F80D-471F-A48E-82B40B061DAF Q33671802-4D4615B1-1B00-4CE3-9323-7C7B5B79A639 Q33691544-66ACB0BE-4707-4FE0-BA1D-B807F7FC340D Q33699378-3AB4E7A5-7186-447F-ABA3-5E87726654F8 Q33716552-64197BA1-530A-4141-82B0-A01DDE8F15D8 Q33719411-2117DBF3-6C28-44E2-87DC-EFE2355A68D2 Q33727426-6CE39746-F5CF-410F-9B6A-F639876A51D8 Q33740638-2F316B59-B66B-4931-8F26-A159826C76CC Q33770769-FDCBC49F-4062-45DE-B746-09F093402C37 Q33823535-1F653848-CB97-4571-B5F3-CBA7B8456A29 Q33833156-5CF4DD6B-4C6C-45D9-A7C7-B5D523924786 Q33918198-FAC07944-B857-4EFA-B4A7-F1A7705E1D91

P2860

Cancer-specific mutations in PIK3CA are oncogenic in vivo

http://www.wikidata.org/entity/Q34335169

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@ast

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@en

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@nl

type

label

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@ast

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@en

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@nl

prefLabel

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@ast

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@en

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@nl

P1433

Q34335169-4C46EA06-3AFB-44B3-99D9-85BF4124CB39

P1476

Q34335169-034189C4-91A9-44D3-8574-962169711DC3

P2093

Q34335169-764EACAA-9A93-4368-A4C5-1417688F0795

Q34335169-DBC6EAB6-D8D2-4C55-95AD-3E80F2295302

P2860

Q34335169-136242B1-A889-488F-9613-BE5338B4E8A3

Q34335169-301A9BFE-9469-4CC6-9A1E-95455E511DBA

Q34335169-38B3939B-99EA-4C43-83D7-78FFB662FA59

Q34335169-3B8989DA-F5B4-4048-9DA6-AAF428B5CBAD

Q34335169-470C99D5-C90D-4BCD-8694-4D64B3A61270

Q34335169-50C6F22B-5303-4201-B281-06C9F9AAD171

Q34335169-547F423C-597A-4AB0-9F28-B48E92402704

Q34335169-5A7AE1F6-C092-4685-BAAB-EE4A1F78FF46

Q34335169-5E913BDE-BE65-4A14-ACD2-BA909D33866A

Q34335169-5F5F359D-D2E0-496E-AF27-4AAF5CAB4E46

P304

Q34335169-DA6CB5F4-034D-41F4-AB0A-B056E9E6491F

P31

Q34335169-B592DC66-3D6D-4B9E-AD59-BD5EB47C6630

P356

Q34335169-9F443BAC-F47B-4F50-8F04-A924512B4DA3

P407

Q34335169-7002E9F8-3878-4778-9294-B2D8AE8DD6BC

P433

Q34335169-BAD30B2B-0773-469B-9184-2B27C092958C

P478

Q34335169-003AF9D4-6AEC-4720-821D-6DAEA443D177

P50

Q34335169-95A1428C-939B-452C-B988-8032B4A42435

P577

Q34335169-FF933BCD-FB72-4C67-8A43-A142D8FEE52F

P5875

Q34335169-47456B43-CBE8-45D1-98A8-8A7493FC9D78

P698

Q34335169-427D3C32-CC8B-4985-BD89-AFA1F840171D

P932

Q34335169-B345810C-8983-4500-BB96-C9C09D455290

P356

PNAS.0510857103

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Cancer-specific mutations in PIK3CA are oncogenic in vivo

@en

P2093

Andreas G Bader

http://www.w3.org/2001/XMLSchema#string

Sohye Kang

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations of PIK3CA in gastric adenocarcinoma

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

High frequency of mutations of the PIK3CA gene in human cancers

PIK3CA as an oncogene in cervical cancer

Signaling by distinct classes of phosphoinositide 3-kinases

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

Phosphoinositide kinases

P304

1475-1479

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0510857103

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7341388

http://www.w3.org/2001/XMLSchema#string

P698

16432179

http://www.w3.org/2001/XMLSchema#string

P932

1360603

http://www.w3.org/2001/XMLSchema#string